Related Experiment Video

Updated: Mar 12, 2026

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

809

Re: HER2 as a Target in Invasive Urothelial Carcinoma

Sam S Chang

    The Journal of Urology
    |November 16, 2016
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis
    09:28

    Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis

    Published on: May 12, 2019

    10.9K
    Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors
    11:52

    Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

    Published on: June 18, 2013

    11.5K

    Related Experiment Videos

    Last Updated: Mar 12, 2026

    Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
    08:28

    Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

    Published on: May 9, 2025

    809
    Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis
    09:28

    Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis

    Published on: May 12, 2019

    10.9K
    Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors
    11:52

    Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

    Published on: June 18, 2013

    11.5K

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    9.0K
    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    9.0K
    Mitogens and the Cell Cycle02:38

    Mitogens and the Cell Cycle

    8.3K
    Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
    8.3K

    Articles linked to this work by shared authors, journal, and citation graph.

    Development and validation of a computational histology artificial intelligence-powered prognostic biomarker in muscle-invasive bladder cancer.

    Urologic oncology·2026

    Durable Responses and Cystectomy Avoidance with IL-15 Receptor Agonist NAI plus BCG in BCG-Unresponsive NMIBC with Carcinoma In Situ ± Papillary Disease.

    The Journal of urology·2026

    Management of Xanthogranulomatous Pyelonephritis: A Review of Current Evidence and Treatment Strategies and a Proposed Clinical Management Algorithm.

    Urology·2026

    Cost-Effectiveness of Immune Checkpoint Inhibitor Therapy Plus Bacillus Calmette-Guérin for High-Risk Nonmuscle-Invasive Bladder Cancer: Analyses of CREST, POTOMAC, and ALBAN.

    The Journal of urology·2026

    Noninvasive Urine Test Predicts Grade Group Upgrading in Patients on Active Surveillance for Prostate Cancer: Multisite Validation and Comparison with MRI.

    The Journal of urology·2026

    Longitudinal Trends in Urology In-service Examination Performance: 2016-2023.

    Urology·2026

    Factors and Reasons Influencing Compliance with Post-vasectomy Semen Analysis: A Systematic Review.

    The Journal of urology·2026

    Anastomotic Urethroplasty is Associated with a Lower Risk of Stricture Recurrence Compared to Buccal Mucosa Graft Onlay after Reconstruction for Radiation-Induced Bulbomembranous Urethral Stenosis.

    The Journal of urology·2026

    Non-Muscle Invasive Recurrence and Management During Surveillance in Patients with Muscle-Invasive Bladder Cancer Who Achieve Clinical Complete Response to Neoadjuvant Chemotherapy.

    The Journal of urology·2026

    TESTOSTERONE THERAPY IN MEN ON ACTIVE SURVEILLANCE FOR PROSTATE CANCER IS NOT ASSOCIATED WITH INCREASED RISK OF DISEASE PROGRESSION.

    The Journal of urology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us